Provided by Tiger Trade Technology Pte. Ltd.

IO Biotech, Inc.

0.7517
+0.05507.89%
Post-market: 0.7283-0.0234-3.11%19:47 EST
Volume:804.66K
Turnover:591.48K
Market Cap:54.08M
PE:-0.56
High:0.7599
Open:0.7135
Low:0.6903
Close:0.6967
52wk High:2.79
52wk Low:0.3234
Shares:71.95M
Float Shares:31.16M
Volume Ratio:0.71
T/O Rate:2.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3356
EPS(LYR):-1.4494
ROE:-240.48%
ROA:-88.58%
PB:59.37
PE(LYR):-0.52

Loading ...

Company Profile

Company Name:
IO Biotech, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
80
Office Location:
Ole MaalOees Vej 3,Copenhagen N,Copenhagen,Capital Region of Denmark,Denmark
Zip Code:
2200
Fax:
- -
Introduction:
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Directors

Name
Position
Mai Britt Zocca
Chief Executive Officer and Director
Peter Hirth
Chairman
Christian Elling
Independent Director
David V. Smith
Independent Director
Heidi Hunter
Independent Director
Helen Collins
Independent Director
Kathleen Sereda Glaub
Independent Director

Shareholders

Name
Position
Mai Britt Zocca
Chief Executive Officer and Director
Amy Sullivan
Chief Financial Officer and Principal Accounting Officer
Devin W. Smith
General Counsel
Qasim Ahmad
Chief Medical Officer